National "major new drug creation" results Dabohua was approved for listing.

Medicine Network October 10th, October 9th, the anti-tumor drug Dabohua officially obtained the state drug regulatory authority's listing approval.
the drug is used to treat diffuse large B-cell lymphoma, fyratic lymphoma, chronic lymphocytic leukemia, etc. Zhou Hui, vice president of biomedical science and strategic oncology at
Xinda, said that as a result of the country's "major new drug creation", Dabohua's listing will effectively reduce the cost of drug use for relevant patients, improve access to clinical drugs, and better meet the needs of the people for high-quality biological drugs.
malignant lymphoma is the most common malignant tumor of the blood system, the incidence rate has been increasing in recent years.
diffuse large B-cell lymphoma, fyratic lymphoma and chronic lymphocytic leukemia, all belong to B-cell non-Hodgkin's lymphoma.
expression of CD20 on the surface of tumor cells is a common feature of these diseases.
Zhou Hui, said Dabohua is a monoclonal antibody targeted at CD20.
He describes it as a guided missile in general, precisely binding to CD20 molecules, on the one hand activating immune cells, so that immune cells produce cytotoxic effects, leading to tumor cell disintegration and destruction, and ultimately "kill" tumor cells;
also reported that lysoxi monoantigen, developed by Roche Pharmaceuticals' Genente, is the first monoclonal antibody drug to be used to treat cancer and was launched in China in 2000.
, many patients could not afford to import drugs, resulting in a failure to receive good treatment.
's approval also means high-quality and affordable lysoxi monoantigen injections for more Chinese patients.
is jointly developed by Xinda Biopharmaceutical Group and Lilly Pharmaceutical Group.
this is also the fourth monoclonal antibody drug approved by Xinda Bio, after Daboshu, Da yutong and Sully-Reliance.
Said that single anti-drug with high specificity, strong targeting and low toxic side effects and other characteristics, by many international pharmaceutical companies.
established in 2011, they have identified the goal of developing high-quality bio-innovative drugs of international standards, focusing on the field of antibody drugs and developing multiple monoclonal antibody drugs.
(Complete)